Tonix Pharmaceuticals (NASDAQ:TNXP) vs. Voyager Therapeutics (NASDAQ:VYGR) Critical Review

Voyager Therapeutics (NASDAQ:VYGR) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Voyager Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Profitability

This table compares Voyager Therapeutics and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Institutional and Insider Ownership

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Voyager Therapeutics and Tonix Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1	0	2	1	2.75
Tonix Pharmaceuticals	1	0	0	2	3.00

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 515.67%. Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 148.48%. Given Voyager Therapeutics’ higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Tonix Pharmaceuticals.

Valuation and Earnings

This table compares Voyager Therapeutics and Tonix Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37 million	4.09	-$119.72 million	($1.80)	-1.49
Tonix Pharmaceuticals	$13.11 million	12.90	-$124.02 million	($12.94)	-0.76

Voyager Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Voyager Therapeutics beats Tonix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.